We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Nuformix Plc | LSE:NFX | London | Ordinary Share | GB00BYW79Y38 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.01 | -5.00% | 0.19 | 2,652,375 | 16:35:09 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.18 | 0.20 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | -859k | -0.0012 | -1.67 | 1.49M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:27:00 | O | 74,431 | 0.1925 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 19/3/2024 | 14:39 | UK RNS | Nuformix PLC Result of AGM |
| 01/3/2024 | 10:31 | ALNC |  IN BRIEF: Nuformix announces subscription to raise GBP150,000 |
| 01/3/2024 | 07:00 | UK RNS | Nuformix PLC Subscription to raise £150,000 |
| 15/1/2024 | 11:30 | UKREG | Nuformix PLC Posting of Annual Report and Notice of AGM |
| 03/1/2024 | 10:16 | ALNC | IN BRIEF: Nuformix narrows annual loss as develops drug assets |
| 03/1/2024 | 07:00 | UKREG | Nuformix PLC Results for the period ended 30 September 2023 |
| 18/12/2023 | 07:00 | UKREG | Nuformix PLC NXP001 Update |
| 23/10/2023 | 12:38 | ALNC | Nuformix gets patent in Japan for pulmonary fibrosis treatment NXP002 |
| 23/10/2023 | 07:04 | UKREG | Nuformix PLC Notice of Allowance of NXP002 Patent in Japan |
| 18/9/2023 | 10:20 | ALNC | IN BRIEF: Nuformix to receive milestone payments from Oxilio pact |
Nuformix (NFX) Share Charts1 Year Nuformix Chart |
|
1 Month Nuformix Chart |
Intraday Nuformix Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 17/4/2024 | 17:52 | NUFORMIX September 2 Presentations - Massive Upside NFX | 457 |
| 18/5/2023 | 07:08 | Nuformix plc | 9,116 |
| 28/1/2021 | 15:43 | ****NFX2021**** | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 15:27:02 | 0.19 | 74,431 | 143.28 | O |
| 15:25:02 | 0.19 | 611,448 | 1,131.18 | O |
| 15:24:35 | 0.18 | 631,579 | 1,136.84 | O |
| 15:17:56 | 0.19 | 253,540 | 488.06 | O |
| 10:50:19 | 0.18 | 526,313 | 947.36 | O |
| Top Posts |
|---|
Posted at 26/4/2024 09:20 by Nuformix Daily Update Nuformix Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker NFX. The last closing price for Nuformix was 0.20p.Nuformix currently has 744,309,368 shares in issue. The market capitalisation of Nuformix is £1,488,619. Nuformix has a price to earnings ratio (PE ratio) of -1.67. This morning NFX shares opened at - |
Posted at 01/3/2024 20:27 by institutional investments Further work had to be done. It's not freeThis wait for a subscription held price down It's complete now Only relevant news to follow |
Posted at 01/3/2024 20:26 by institutional investments Now, it can't be a surprise since the updates last May ?"The combined data gives us great confidence in NXP002's potential as an inhaled therapy for IPF treatment and allows the Company to tell a more complete pre-clinical story to potential licensing partners for the first time. We will now look for opportunities to share this important new data with key players in the rare disease and respiratory disease sectors as we explore all opportunities to progress the NXP002 programme." |
Posted at 01/3/2024 09:18 by vlad the impaler Excellent RNSLast raise ore newsflow so meme the most of price |
Posted at 01/3/2024 08:49 by nobbygnome He’s the sad guy who has 20 odd sock puppets which pollute many threads on this BB. He generally shorts everything but bizarrely he’s long NFX and SYME which are 2 disastrous investments! He went long on SYME at just below 0.6; its now 0.03!!!!His other funny disaster recently is aggressively shorting RR. at 310 ahead of the results. It’s now 370p😂㈳ |
Posted at 08/2/2024 12:36 by peverill Give it a few more weeks,nothing too lose now given the price. |
Posted at 05/2/2024 22:20 by institutional investments Dint mind the fall back yet. It's above right price still. But news expected, and really would like it to be this very week |
Posted at 30/1/2024 07:29 by peverill Thought we might have a reassuring RNS,that everything is moving ok and the company sees no reason for a 25% drop in its share price.But hopefully there wasn't the need. |
Posted at 29/1/2024 14:38 by vlad the impaler Seems a good price. Will need the ping for profit but it can't be too far away after today |
Posted at 06/1/2024 16:59 by jotoha2 The imperialist , not to sure why you think I joined ADVFN IN Dec , have been a member for many years , as for NFX have been buying for over a year , am expecting some serious returns here if a deal is completed , very happy to wait another 12 months for payday. |
Posted at 14/12/2021 17:53 by sentiment riles Lanstead Investment – Q&AQ. Why did Nuformix choose the Sharing Agreements with Lanstead? A: The sharing agreements with Lanstead allows Nuformix to benefit from positive share price performance over 20 months and the funding supports Nuformix’s activities over that period. We see a number of positive catalysts for Nuformix over the coming months, in particular as we make NXP004 Phase 1 ready and continue to strengthen the IP around NXP004, which should be positive for the share price as these are announced. Q: Is Lanstead entitled to invest monthly at a fixed discount to the prevailing Nuformix share price from month-to-month? A: No. Lanstead will be issued and will immediately pay for the shares it subscribes for at 1.5p per share. The number of shares issued to Lanstead is fixed and does not change. However, the amount from Lanstead due to the Company under the sharing agreements is adjustable upwards or downwards at each of the 20 monthly settlements that follow. For example; the approximate amount in any particular month will be 10% more than £82,500 if the share price is 10% higher than the 2.0p benchmark price (“BMP”) or 10% less than £82,500 if the share price is 10% lower than the BMP. Q: Can Lanstead benefit by the share price being lower than the 2.0p BMP, rather than going higher than 2.0p? A: No. Lanstead makes more money the higher the share price is. Through the sharing agreements Lanstead shares some, but not all, of the upside when the share price appreciates with Nuformix. The sharing agreements are an incentive for Nuformix to perform, thereby benefitting all shareholders including Lanstead. If the share price over 20 months averages double the BMP (i.e. 4.0p) then the Company will receive double the initial Lanstead subscription of £1.65 million (i.e. £3.30 million instead of £1.65 million). If the share price over 20 months averages half the BMP (i.e. 1.0p) then the Company will ultimately receive half the initial Lanstead subscription (i.e. £0.825 million instead of £1.65 million). The projected outcome for Nuformix is contractually clear and the value of Lanstead’s investment is greater if the company’s share price is higher. It is important to note that Lanstead participates in the majority, but not all of the upside in any future Nuformix share price appreciation. The bottom line is that Lanstead makes more money as the share price rises and does not derive any advantage from a decline in the share price. Q: Can Lanstead trade its Nuformix shares? A: Lanstead has a demonstrable track record of being a longer-term supportive shareholder to its investee companies. Like any institutional investor Lanstead only invests in companies where it can see strong potential for share price appreciation. Lanstead is free to buy and sell shares just like any other shareholder and it is required to disclose movements of >1% as a significant disclosable shareholder. Unlike other shareholders, Lanstead has an uncapped commitment through the sharing agreements to remit amounts each month to Nuformix based on the prevailing share price. Therefore whilst Lanstead may take a profit along the way (like any shareholder) and cover its downside risk on the investment (just like any shareholder), Lanstead also has an incentive (unlike other shareholders) to maintain a significant on-going shareholding because of its uncapped exposure on the amounts due to Nuformix over the 20 months of the sharing agreements should the Nuformix shares appreciate |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
